Prosecution Insights
Last updated: October 02, 2026
Application No. 18/571,558

SUSPENDING POLYMER COMPOSITION AND METHOD OF USE THEREOF

Final Rejection §103§DP
Filed
Dec 18, 2023
Priority
Jun 16, 2021 — provisional 63/211,201 +2 more
Examiner
WERTZ, ASHLEE ELIZABETH
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Isp Investments LLC
OA Round
2 (Final)
53%
Grant Probability
Moderate
3-4
OA Rounds
7m
Est. Remaining
95%
With Interview

Examiner Intelligence

Grants 53% of resolved cases
53%
Career Allowance Rate
27 granted / 51 resolved
-7.1% vs TC avg
Strong +42% interview lift
Without
With
+42.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
57 currently pending
Career history
107
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
48.4%
+8.4% vs TC avg
§102
6.7%
-33.3% vs TC avg
§112
15.9%
-24.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 51 resolved cases

Office Action

§103 §DP
DETAILED ACTION Previous Rejections Applicant’s arguments, filed June 11, 2026, have been fully considered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. Claim Rejections - 35 USC § 103 (Maintained) The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 5-14 are rejected under 35 U.S.C. 103 as being as being obvious over Clark et al. (US 6,025,311) in view of Dijk et al. (US 2008/0071077 A1). Regarding claims 5 and 11, Clark discloses a composition including 15.0 wt.% hydroxypropyl methyl cellulose (HPMC), 8.0 wt.% carboxymethyl cellulose (CMC), and 0.2 wt.% xanthan gum (Col 9, Table 7C). In relation to the total amount of polymers, this is 64.65 wt.% HPMC, 34.48 wt.% CMC, and 0.86 wt.% of xanthan gum. The polymer blends are added to shampoo formulations as thickeners in an amount such as 1.80 wt.% (Col 11, lines 30-34; Col 12-13). The shampoo compositions include anionic surfactants, such as 27.50 wt.% of ammonium lauryl sulfate, preservatives, such as 0.1 wt.% of methyl paraben, and around 60 wt.% water (Col 12, lines 30-40, Table 12). The shampoo compositions are free from acrylic acids, methacrylates, or derivatives. Additionally, Clark discloses that hydroxypropyl methyl cellulose acts as a thickener (Col 2, lines 65-67), that adding CMC allows for the salt requirement to be reduced (Col 8, lines 55-59), and that xanthan gum provides a structure to the polymer suspension which helps prevent settling of the polymer particles (Col 4, lines 9-11). Clark is not believed to be anticipatory because Clark does not disclose amounts of each component falling within the instantly claimed range. That is, Clark discloses the amount of xanthan gum in the polymer blend is 0.86 wt.%, which is lower than the claimed amount of about 10-25 wt.%, and the amount of CMC in the polymer blend is 34.48 wt.%, which is higher than the claimed amount of about 10-25 wt.%. However, Dijk discloses the use of CMC, HPMC, and xanthan gum as thickeners in personal care compositions such as shampoos [0016]-[0018]. Dijk teaches that the weight ratio of CMC to HPMC or xanthan gum may be from 1:100 to 100:1 [0018]. CMC, HMPC, and xanthan gum, and their amounts, are recognized to have different effects (HPMC, CMC, and xanthan gum – thickening; CMC – reducing salt requirement; xanthan gum – providing structure to polymer suspension) with changing amounts used as taught by Clark; and the general condition (ratio of the components) is known (Dijk [0018]). As such, result effective variables can be optimized by routine experimentation and it would not have been inventive for the skilled artisan to have discovered the optimum amount of CMC, HPMC, and xanthan gum in the polymer combination via routine experimentation. See MPEP 2144.05. In regards to the amount of the individual components (such as the surfactant and personal care ingredient), in the case where the claimed ranges “overlap or lie inside ranges disclosed by the prior art” a prima facie case of obviousness exists. See MPEP 2144.05 A. Regarding claim 6, the amounts of HPMC, CMC, and xanthan gum would be achieved by one of ordinary skill in the art through routine experimentation, as previously discussed. Clark does not disclose that the carboxymethyl cellulose has a degree of substitution of less than 0.65. Dijk teaches the use of CMC which has a degree of substitution of 0.6 [0026]. Dijk teaches that the CMC of the disclosure provides the cosmetic formulations, such as shampoos, with improved rheological behavior, gelling properties, texture and elasticity, enhanced water retention and (storage) stability [0010]-[0011] [0016]. Since Clark generally teaches a polymer combination to thicken personal care compositions, such as shampoos, it would have been prima facie obvious to one of ordinary skill in the art to include the CMC of Dijk, with a degree of substitution of 0.6, within the teachings of Clark, because Dijk teaches a CMC with this degree of substitution in cosmetic formulations such as shampoos. An ordinarily skilled artisan would be motivated to use a CMC with a degree of substitution of 0.6 because Clark teaches that it provides the cosmetic formulations with improved rheological behavior, gelling properties, texture and elasticity, enhanced water retention and (storage) stability [0010]-[0011] [0016]. A prima facie case of obviousness exists because of overlap, as previously discussed. Claims 7-8 and 14 are rendered prima facie obvious because Clark discloses the shampoo composition includes a preservative (methyl paraben) (Col 12, lines 30-40). Claims 9-10 are rendered prima facie obvious because Clark discloses the compositions are formulated into shampoos (Col 11, lines 30-34; Col 12-13). Claim 12 is rendered prima facie obvious because Clark discloses ammonium lauryl sulfate (Col 12, lines 30-40) which is an alkyl sulfate anionic surfactant. Claim 13 is rendered prima facie obvious because the compositions disclosed by Clark used as a shampoo are silicone free (Col 11, lines 30-34; Col 12-13). Response to Arguments Applicant’s arguments filed 06/11/2026 have been fully considered but are not persuasive. Applicant argues at pg. 9-11 that the Office has failed to establish a prima facie case of obviousness because the claimed ranges for xanthan gum and carboxymethyl cellulose are not merely close to Clark, and Dijk does not provide the specific motivation to select the presently claimed combination. The Examiner disagrees. A prima facie case of obviousness has been established because it would have been prima facie obvious to achieve the claimed ranges of CMC, HMPC, and xanthan gum through routine experimentation. CMC, HMPC, and xanthan gum, and their amounts, are recognized to have different effects (HPMC, CMC, and xanthan gum – thickening; CMC – reducing salt requirement; xanthan gum – providing structure to polymer suspension) with changing amounts used as taught by Clark; and the general condition (ratio of the components) is known (Dijk [0018]). As such, result effective variables can be optimized by routine experimentation and it would not have been inventive for the skilled artisan to have discovered the optimum amount of CMC, HPMC, and xanthan gum in the polymer combination via routine experimentation. See MPEP 2144.05. Applicant further argues at pg. 11 that routine experimentation is only a proper basis for an obviousness rejection where the claimed ranges overlap or are proximate to those disclosed by the prior art, and where a result-effective variable is recognized by the skilled artisan, which is not the case here. The Examiner disagrees. Each of the claimed polymers are known to achieve a recognized result (HPMC, CMC, and xanthan gum – thickening; CMC – reducing salt requirement; xanthan gum – providing structure to polymer suspension), therefore it would not have been inventive for the skilled artisan to have discovered the optimum amount of CMC, HPMC, and xanthan gum in the polymer combination via routine experimentation. Generally, differences in concentration will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration is critical. See MPEP 2144.05.II.A. Applicants can rebut a prima facie case of obviousness by showing the criticality of the claimed range. See MPEP 2144.05.III.A. In the instant case, the applicant has not shown that the particular range is critical (generally by showing that the claimed range achieves unexpected results relative to the prior art range). Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 5-14 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-24 of U.S. Patent No. 12,624,313 in view of Clark et al. (US 6,025,311). Although the claims at issue are not identical, they are not patentably distinct from each other. The claims recite all of the features instantly recited for the composition except for carboxymethyl cellulose. Clark discloses a personal care composition including carboxymethyl cellulose (CMC) (Col 9, Table 7C). Clark teaches that that adding CMC allows for the salt requirement to be reduced (Col 8, lines 55-59). It would have been prima facie obvious to one of ordinary skill in the art to include CMC, within the claims. The ordinarily skilled artisan would have been motivated to formulate the composition to include CMC to reduce the salt requirement (Col 8, lines 55-59). The weight percentages of each component, as recited in the instant claims, would be achieved by one of ordinary skill in the art through routine optimization. See MPEP 2144.05(II)(A). Response to Arguments Applicant’s arguments filed 06/11/2026 have been fully considered but are not persuasive. Applicant argues that the claims of 12,624,313 recite cetyl-HEC which is absent from the claims of the present application, therefore, the claims of the present application are patently distinct from the claims of 12,624,313. The Examiner disagrees because the claims recite all of the features instantly recited for the claimed composition except for carboxymethyl cellulose and the ordinarily skilled artisan would have been motivated to formulate the composition to include CMC to reduce the salt requirement as taught by Clark (Col 8, lines 55-59). Therefore, the claims of the instant application are not patentably distinct from the claims of 12,624,313. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ashlee E Wertz whose telephone number is (571)270-7663. The examiner can normally be reached Monday - Friday, 8 AM - 5 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana Kaup can be reached at 571-272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ASHLEE E WERTZ/Examiner, Art Unit 1612 /SAHANA S KAUP/Supervisory Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Dec 18, 2023
Application Filed
Feb 11, 2026
Non-Final Rejection mailed — §103, §DP
Jun 11, 2026
Response Filed
Aug 11, 2026
Final Rejection mailed — §103, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12708618
PHARMACEUTICAL COMPOSITE FORMULATION COMPRISING PROTON PUMP INHIBITOR AND ANTACID, AND METHOD FOR PREPARING SAME
3y 7m to grant Granted Aug 18, 2026
Patent 12702632
PROTEASE FORMULATION FOR TREATMENT OF MICROBIAL INFECTIONS
3y 9m to grant Granted Aug 11, 2026
Patent 12673015
LOW SULFATE SURFACTANT COMPOSITION
3y 11m to grant Granted Jul 07, 2026
Patent 12660823
FUNGICIDAL COMBINATIONS
3y 6m to grant Granted Jun 23, 2026
Patent 12642797
COATED GRANULE, SOLID DISPERSION, AND PREPARATION CONTAINING VORTIOXETINE HYDROBROMIDE FOR ORAL TASTE MASKING
4y 5m to grant Granted Jun 02, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
53%
Grant Probability
95%
With Interview (+42.1%)
3y 4m (~7m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 51 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month